MedPath

Retro-PROFIT; PReservation Of female Fertility In oncologic Treatment Fertility, pregnancy and quality of life after fertility-sparing treatment for gynaecological cancer.

Recruiting
Conditions
cervical cancer
endometrial cancer
gynaecological cancer
ovarian cancer
10038594
10010273
10013356
Registration Number
NL-OMON53845
Lead Sponsor
eids Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
1030
Inclusion Criteria

- Women with cervical, ovarian or endometrial cancer
- Age between 18-39 at time of diagnosis
- Fertility-sparing treatment between 2000 and 2020

Exclusion Criteria

For the questionnaire and interviewstudy:
- Living abroad and untraceable at time of data collection
- Deceased at time of data collection
- Insufficient understanding of the Dutch language

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Q1: 2-year and 5-year recurrence free survival<br /><br><br /><br>Q2:Percentage of women trying to conceive, within this group: pregnancy rate<br /><br>(number of first pregnancies after treatment divided by the number of women who<br /><br>tried to conceive) and number of pregnant women divided by the number of women<br /><br>who tried to conceive after treatment.<br /><br>Live birth rate<br /><br><br /><br>Q3:Initiation of pursuing pregnancy<br /><br>Psychological outcome: reproductive concerns, anxiety and depression, cancer<br /><br>worries and decisional regret. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Q1: 2- and 5-year survival and overall survival Q2:Type of conception<br /><br>(artificial or spontaneous) Miscarriages, gestational age at delivery (preterm<br /><br><28 weeks, preterm 28-32 weeks, preterm 32-37 weeks, term), mode of delivery<br /><br>(induction, caesarean section, spontaneous labor)</p><br>
© Copyright 2025. All Rights Reserved by MedPath